Pharma times RSS Feed

The news arrives after the tenth recorded positive Omicron case in Scotland, which the government has confirmed has no previous connection to the previous nine.

The new development will arm healthcare providers with a vital tool to address the steep rise of malaria cases in children living in Africa.

Researchers have identified in those patients experiencing blood clots after vaccination a subsequent condition referred to as vaccine-induced immune thrombotic thrombocytopenia (VITT).

Scientists and health experts have cautioned that the new variant could have the ability to bypass the effectiveness of vaccines that are currently available.

Amid the COVID-19 pandemic, the NHS faces staff and hospital equipment shortages alongside the growing need to reduce the backlog in patient surgeries and treatments.

The UK government has aimed to expand their COVID-19 vaccination programme, in accordance with guidance from the Joint Committee on Vaccination and Immunisation (JCVI).

The Scottish government aims to expand and advance their COVID-19 booster programme, following the six cases of the Omicron variant that were reported as of Monday 29 November. This decision is based on advice from the Joint Committee on Vaccination and Immunisation (JCVI).

Following its recent approval of an injectable HIV-1 treatment from the National institute for Health and Care Excellence (NICE), GlaxoSmithKline (GSK) has high hopes in developing a cure for the virus in the future.

An additional six cases of the Omicron variant have now been detected in Scotland, bringing the UK total so far to nine.

Analyses provided by UK cancer charity Macmillan has provided insights into the repercussions experienced by patients waiting to receive treatment during the COVID-19 pandemic.

After hosting a virtual ceremony in 2020, this year’s awards returned to the Royal Lancaster London hotel

Data from the UK’s Health Security Agency (UKHSA) has revealed that COVID-19 vaccines are safe in pregnancy.

The Food and Drug Administration (FDA) granted approval for emergency use of the Comirnaty vaccine in children in October 2021.

A team of scientists and pharmaceutical collaborators have discovered a ‘bench to bedside’ drug design, which will hopefully improve the future treatment of Alzheimer’s disease.

The use of molnupiravir in COVID-19 cases aims to reduce the pressure on hospitals, in turn reducing the risk of patients developing more severe symptoms of the virus.

The leading UK preganancy and baby loss charity Tommy’s have said with the approval of the hormonal drug, as many as 8,450 miscarrages a year could be prevented.

With the latest approval from the EC, patients in Europe suffering from metastatic triple-negative breast cancer can now receive Gilead Science’s Trodelvy as part of their treatment.

NICE has published draft guidance recommending risdiplam (Evrysdi) as part of a managed access agreement (MAA) for the treatment of the rare genetic disorder spinal muscular atrophy (SMA).

Nykode Therapeutics, a clinical-stage biopharmaceutical company, announced that it has entered into a collaboration agreement with Regeneron.

The approval of Covaxin follows the WHO Emergency Use Listing for the vaccine